Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2017; 16: 48-54
Динамика изменений стабилометрических параметров у детей с синдромом опсоклонус-миоклонус при проведении различных реабилитационных методик
https://doi.org/10.24287/1726-1708-2017-16-3-48-54Аннотация
Список литературы
1. Gorman M.P. Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia syndrome. Current opinion in pediatrics 2010; 22 (6): 745-50.
2. Pang K.K., et al. A prospective study of the presentation and management of dancing eye syndrome/opsoclonus myoclonus syndrome in the United Kindom. Eur J Pediatr Neurol 2010; 14: 156-61.
3. Herman T.E., Siegel M.J. Ataxia without opsoclonus: right lumbar sympathetic trunk neuroblastoma. Clin Pediatr 2009; 48: 336-40.
4. Krug P., et al. Opsoclonus-myoclonus in children associated or not with neuroblastoma. Eur J Pediatr Neurol 2010; 14: 400-9.
5. Mitchell W.G., et al. Effect of Increased Immunosuppression on Developmental Outcome of Opsoclonus Myoclonus Syndrome (OMS). J Child Neurol 2015; 30 (8): 976-82.
6. Pless M., Ronthal M. Treatment of opsoclonus-myoclonus with high-dose intravenous immunoglobulin. Neurology 1996; 46 (2): 583-4.
7. Krug P., et al. Opsoclonus-myoclonus in children associated or not with neuroblastoma. Eur J Paediatr Neurol 2010; 14 (5): 400-9.
8. Herman T.E., Siegel M.J. Ataxia without opsoclonus: right lumbar sympathetic trunk neuroblastoma. Clin Pediatr (Phila) 2009; 48 (3): 336-40.
9. Rostásy K., et al. High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome. Neuropediatr 2006; 37 (5): 291-5.
10. Kinsbourne M. Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatry 1962; 25 (3): 271-6.
11. Boltshauser E., Deonna T., Hirt H.R. Myoclonic encephalopathy of infants or “dancing eyes syndrome”. Report of 7 cases with long-term follow-up and review of the literature (cases with and without neuroblastoma). Helv Pediatr Acta 1979; 34 (2): 119-33.
12. Mitchell W.G., et al. Effect of Increased Immunosuppression on Developmental Outcome of Opsoclonus Myoclonus Syndrome (OMS). J Child Neurol 2015; 30 (8): 976-82.
13. Krasenbrink I., et al. Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS). Neuropediatr 2007; 38 (3): 114-6.
14. Pranzatelli M.R., et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pedi-atr Hematol Oncol 2006; 28 (9): 585-93.
15. Pranzatelli M.R., et al. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil. J Child Neurol 2009; 24 (3): 316-22.
16. de Grandis E., et al. Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome. Neuropediatr 2009; 40 (3): 103-11.
17. Upledger J.E. Craniosacral therapy. Phys Ther 1995; 75 (4): 328-30.
Pediatric Hematology/Oncology and Immunopathology. 2017; 16: 48-54
Dynamics of the stabilometric parameters in children with the opsoclonus myoclonus syndrome in carrying out various rehabilitation methods
https://doi.org/10.24287/1726-1708-2017-16-3-48-54Abstract
Optimization of the choice of rehabilitation methods in children with the oploskonus myoclonus syndrome on the basis of the analysis of stabilometric parameters. The study included 48 children of both sexes in the age range from 3 to 7 years with the diagnosis of «opsclonus-myoclonus syndrome». All patients were separated into 4 groups according to applied rehabilitation methods: in the first group (12 patients) patients received craniosacral therapy, in the II group - modified Vojta therapy (13 patients), in the third group patients underwented an isolated course of Galileo vibration therapy (10 patients), in the fourth group patients received modified Vojta therapy together with Galileo vibration therapy (13 patients). Patients underwented the course of craniosacral therapy demonstrated the increases rates of speed (V) in 1.48 times and statokinesiogram square in 1.94 times after fifth procedure as compared with data before. In the second group 1.32 times speed decrease (V) and 1.56 statokinesiogram square decrease (S) were marked. In the third group there were 1.73 times statokinesiogram square increase (S) and the displacement of pressure center midposition in frontal plane (X) to the left after implementation of 10 manipulation. In the fourth group 1.42 times speed decrease (V) and 2.7 times statokinesiogram square decrease (S) were marked after implementation of 10 manipulation, as well as displacement of pressure center midposition (X) in frontal plane to the right and tendency to displacement of pressure center in sagittal plane to the front after conducted manipulations. Modified Vojta therapy together with Galileo vibration therapy can be applied in the capacity of most effective rehabilitation methods for children with opsoclonus-myoclonus syndrome leading to useful increase of stabilometric parameteres.
References
1. Gorman M.P. Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia syndrome. Current opinion in pediatrics 2010; 22 (6): 745-50.
2. Pang K.K., et al. A prospective study of the presentation and management of dancing eye syndrome/opsoclonus myoclonus syndrome in the United Kindom. Eur J Pediatr Neurol 2010; 14: 156-61.
3. Herman T.E., Siegel M.J. Ataxia without opsoclonus: right lumbar sympathetic trunk neuroblastoma. Clin Pediatr 2009; 48: 336-40.
4. Krug P., et al. Opsoclonus-myoclonus in children associated or not with neuroblastoma. Eur J Pediatr Neurol 2010; 14: 400-9.
5. Mitchell W.G., et al. Effect of Increased Immunosuppression on Developmental Outcome of Opsoclonus Myoclonus Syndrome (OMS). J Child Neurol 2015; 30 (8): 976-82.
6. Pless M., Ronthal M. Treatment of opsoclonus-myoclonus with high-dose intravenous immunoglobulin. Neurology 1996; 46 (2): 583-4.
7. Krug P., et al. Opsoclonus-myoclonus in children associated or not with neuroblastoma. Eur J Paediatr Neurol 2010; 14 (5): 400-9.
8. Herman T.E., Siegel M.J. Ataxia without opsoclonus: right lumbar sympathetic trunk neuroblastoma. Clin Pediatr (Phila) 2009; 48 (3): 336-40.
9. Rostásy K., et al. High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome. Neuropediatr 2006; 37 (5): 291-5.
10. Kinsbourne M. Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatry 1962; 25 (3): 271-6.
11. Boltshauser E., Deonna T., Hirt H.R. Myoclonic encephalopathy of infants or “dancing eyes syndrome”. Report of 7 cases with long-term follow-up and review of the literature (cases with and without neuroblastoma). Helv Pediatr Acta 1979; 34 (2): 119-33.
12. Mitchell W.G., et al. Effect of Increased Immunosuppression on Developmental Outcome of Opsoclonus Myoclonus Syndrome (OMS). J Child Neurol 2015; 30 (8): 976-82.
13. Krasenbrink I., et al. Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS). Neuropediatr 2007; 38 (3): 114-6.
14. Pranzatelli M.R., et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pedi-atr Hematol Oncol 2006; 28 (9): 585-93.
15. Pranzatelli M.R., et al. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil. J Child Neurol 2009; 24 (3): 316-22.
16. de Grandis E., et al. Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome. Neuropediatr 2009; 40 (3): 103-11.
17. Upledger J.E. Craniosacral therapy. Phys Ther 1995; 75 (4): 328-30.
